Research programme: metallo beta-lactamase enzyme inhibitors - Antabio

Drug Profile

Research programme: metallo beta-lactamase enzyme inhibitors - Antabio

Alternative Names: MBLi - Antabio

Latest Information Update: 11 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Antabio
  • Class Small molecules
  • Mechanism of Action Beta lactamase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Gram-negative infections

Most Recent Events

  • 16 Oct 2017 Antabio plans a clinical trial for Gram negative infections in 2019
  • 11 Nov 2016 Preclinical trials in Gram-negative infections in France (unspecified route)
  • 16 Jul 2016 No recent reports of development identified for early research development in Gram-negative-infections in France
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top